d2a

d2a appears to have been a small independent strategic clinical and product development consulting firm serving biotech companies, medical device companies, and academic clients. Public references to the firm are primarily through biographies of its president, Deborah D. Ascheim, M.D., which describe d2a as providing consulting rather than developing its own therapeutic pipeline. There is no clear evidence that d2a operated as a drug developer, platform biotech, or commercial therapeutics company with named assets. The available information suggests it was a healthcare-sector advisory business centered on clinical strategy and product development expertise. Recent public evidence of active standalone operations is limited.